Fresh Food Farmacy
OtherPatients are prescribed fresh food by a dietician, fill the prescription each week at the FFF clinic, receive training on how to use the food, and training in diabetes self management.
NCT Number: NCT03718832
This trial investigates the value created by the highly innovative Fresh Food Farmacy (FFF) program at Geisinger Health. The program provides food-insecure diabetics with healthy food for their entire household: at least two meals per day, five days a week. The program also provides education on how to prepare the food, and education on healthy living including diabetes self management. The research measures the effects of the FFF program on patient health and wellbeing.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Not applicable
Fresh Food Farmacy, Lewistown, Pennsylvania, United States
This is a pragmatic, prospective, randomized controlled trial of Geisinger's Fresh Food Farmacy (FFF) program as the program expands to new sites. Qualifying subjects will be randomized 1:1 to receive either early participation in the FFF program (treatment group) or later participation (control group).
Approximately 500 Geisinger subjects will participate in this study with about half assigned to the treatment group and about half to the control group. The treatment group will begin the program soon after trial recruitment: the "Begin Now" group. The control group will begin the program after 6 months: the "Begin Later" group. Approximately 2000 household members will be included in the data-only portion of the research.
Outcomes will include clinical measures, such as HbA1c, survey responses including self-assessed health measures, and utilization / healthy-behavior measures from EHR and paid claims data. These will be measured for subjects and their household members.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients are prescribed fresh food by a dietician, fill the prescription each week at the FFF clinic, receive training on how to use the food, and training in diabetes self management.
Time frame: 6 months after trial enrollment
Glycated hemoglobin (HbA1c) is a measure of the average share of glucose that has been in the bloodstream over the 2-3 months preceding measurement. HbA1c is measured by performing assays on samples of the participants' blood.
Units are percentages; for differences between HbA1c values, units are percentage points.
An HbA1c value of 6.5% is the lower threshold for type 2 diabetes. HbA1c values are rarely above 15-20%. In the context of this study (patients with type 2 diabetes), higher scores are considered a worse outcome.
Time frame: 12 months after trial enrollment
Glycated hemoglobin. Units are percentages (for differences, percentage points) reflecting the average share of glucose in the bloodstream over the previous 2-3 months.
An HbA1c value of 6.5% is the lower threshold for type 2 diabetes. HbA1c values are rarely above 15-20%.
In the context of this study (patients with type 2 diabetes), higher scores are considered a worse outcome.
Time frame: 6 and 12 months after trial enrollment
Fasting blood glucose is a measure of blood sugar control over a short time period (the blood glucose content after an overnight fast).
Units are mg/dL. To convert to mmol/L (SI), multiply by 0.0113. Lower fasting blood glucose levels indicate better health within the context of this study.
Time frame: 6 and 12 months after trial enrollment
Weight in pounds. In the context of this study, higher values are considered a worse outcome.
SI conversion factor: To convert pounds to kilograms, multiply by 0.4536.
Time frame: 6 and 12 months after trial enrollment
Body Mass Index (BMI) in kg/m^2. BMI is computed using weight (lb) and height (in). The CDC's healthy reference range for BMI among adults aged 20 and older is 18.5 to 24.9. BMI values greater than or equal to 30.0 indicate obesity. In the context of this study, higher BMI is considered a worse outcome.
Time frame: 6 and 12 months after trial enrollment
Total cholesterol in mg/dL. The CDC recommends total cholesterol levels around 150 mg/dL and classifies levels of 200 mg/dL and above as unhealthy (hyperlipidemia). In the context of this study, higher total cholesterol indicates a worse outcome.
SI conversion factor: To convert from mg/dL to mmol/L, multiply by 0.0259.
Time frame: 6 and 12 months after trial enrollment
Low-density lipoprotein (LDL) cholesterol, measured in mg/dL. The CDC recommends LDL levels of 100 mg/dL or below. In the context of this study, higher levels of LDL indicate a worse outcome.
SI conversion factor: To convert from mg/dL to mmol/L, multiply by 0.0259.
Time frame: 6 and 12 months after trial enrollment
High-density lipoprotein (HDL) cholesterol, measured in mg/dL. The CDC recommends HDL levels of at least 40 mg/dL in men and 50 mg/dL in women. In the context of this study, higher levels of HDL indicate a better outcome.
SI conversion factor: To convert mg/dL to mmol/L, multiply by 0.0259.
Time frame: 6 and 12 months after trial enrollment
Triglycerides, measured in mg/dL. The CDC recommends levels of triglycerides below 150 mg/dL. In the context of this study, higher levels of triglycerides indicate worse outcomes.
SI conversion factor: To convert mg/dL to mmol/L, multiply by 0.0113.
Time frame: 6 and 12 months after trial enrollment
Systolic blood pressure, measured in mm Hg. The CDC identifies normal healthy systolic blood pressure as below 120 mm Hg. The American College of Cardiology identifies 120 to 129 mm Hg as elevated blood pressure and 130 mm Hg and higher as hypertensive. Higher systolic blood pressure levels indicate worse outcomes.
Time frame: 6 and 12 months after trial enrollment
Diastolic blood pressure, measured in mm Hg. The American College of Cardiology identifies normal diastolic blood pressure as below 80 mm Hg and elevated/hypertensive diastolic blood pressure as 80 mm Hg or above. Higher levels of diastolic blood pressure indicate worse outcomes.
Time frame: 6 and 12 months after trial enrollment
Patient-reported measure of diet improvement: Number of times in the last 7 days when the patient ate fruit.
Time frame: 6 and 12 months after trial enrollment
Patient-reported measure of diet improvement: Number of times in the last 7 days when the patient ate dark green vegetables.
Time frame: 6 and 12 months after trial enrollment
Patient-reported measure of diet improvement: Number of times in the last 7 days when the patient drank sweetened beverages.
Time frame: 6 and 12 months after trial enrollment
Patient-reported measure of diet improvement: Number of times in the last 7 days when the patient ate fast food, takeout, or at a restaurant.
Time frame: 6 and 12 months after trial enrollment
Patient-reported measure of diet improvement: Survey question: "Do you believe your diet has improved compared to one year ago?".
Time frame: 6 and 12 months after trial enrollment
The proportion of questions testing patients' knowledge of how different factors contribute to blood sugar answered correctly.
Time frame: 6 and 12 months after trial enrollment
Survey-based index score for patient-reported positive engagement outcomes.
Scores range from 0 to 1. Scores are standardized so that the control group always has a mean score of 0 and standard deviation of 1. Higher scores reflect better outcomes---here, better engagement with the program. Scores composite results from multiple survey questions while adjusting for covariance between questions.
Time frame: 6 and 12 months after trial enrollment
Healthcare utilization: Number of outpatient claims among continuously enrolled/insured subjects during the relevant time frame after trial enrollment.
Time frame: 6 and 12 months after trial enrollment
Healthcare utilization: Number of inpatient and emergency department claims among continuously enrolled/insured subjects during the relevant time frame after enrollment.
Time frame: 6 and 12 months after trial enrollment
The number of subjects who were continuously enrolled/insured who had any outpatient claims during the relevant time frame after trial enrollment. For statistical analyses, coefficients and errors represent proportions of participants, relative to the size of the group/treatment arm.
Time frame: 6 and 12 months after trial enrollment
The number of subjects who were continuously enrolled/insured who had any inpatient or emergency department claims during the relevant time frame after trial enrollment. For statistical analyses, coefficients and errors represent proportions of participants, relative to the size of the group/treatment arm.
Time frame: 6 and 12 months after trial enrollment
Healthcare utilization: Total value (USD) of inpatient and emergency department payments among continuously enrolled/insured subjects during the relevant time frame after enrollment.
Time frame: 6 and 12 months after trial enrollment
Healthcare utilization: Value (USD) of outpatient payments among continuously enrolled/insured subjects during the relevant time frame after enrollment.
Time frame: 6 and 12 months after trial enrollment
The number of times an individual participant completed a medical appointment with a dietician in the relevant time frame, based on electronic health records.
Time frame: 6 and 12 months after trial enrollment
The number of times an individual participant completed a Diabetes Self-Management Training (DSMT) in the relevant time frame, based on electronic health records.
Time frame: 6 and 12 months after trial enrollment
The number of times an individual participant completed a medical appointment with an endocrinologist in the relevant time frame, based on electronic health records.
Time frame: 6 and 12 months after trial enrollment
The number of times an individual participant completed a medical appointment regarding weight loss or weight management in the relevant time frame, based on electronic health records.
Time frame: 6 months and 12 months
Healthy behaviors observed in electronic health record, including preventive care and appointments kept
Time frame: 6 months and 12 months
Healthy behaviors observed in paid claims using Healthcare Effectiveness Data and Information Set (HEDIS) measures. These measures were not collected for this study.
Time frame: 6 months and 12 months
HbA1c available in EHR records
Time frame: 6 months and 12 months
Weight in pounds as available in EHR records
Time frame: 6 months and 12 months
BMI in kg/m^2 in pounds as available in EHR records
Time frame: 6 months and 12 months
Cholesterol as available in EHR records
Time frame: 6 months and 12 months
Blood pressure as available in EHR records
Time frame: 6 months and 12 months
Triglycerides as available in EHR records
Time frame: 6 months and 12 months
Fasting glucose as available in EHR records
Time frame: 6 months and 12 months
Inpatient utilization for household members as available in EHR records
Time frame: 6 months and 12 months
Outpatient utilization for household members as available in EHR records
Time frame: 6 months and 12 months
Inpatient utilization for household members as available in paid claims
Time frame: 6 months and 12 months
Outpatient utilization for household members as available in paid claims
Time frame: 6 months and 12 months
Separate results by tercile of baseline HbA1c
Time frame: 6 months and 12 months
Heterogeneity analysis by site of the clinic
Time frame: 6 months and 12 months
Heterogeneity analysis by causal trees using the baseline characteristics to explore heterogeneity, sample size permitting.
John B Bulger, DO
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04639414
Diabetes Mellitus, Diabetes Mellitus, Type 2
Graz, Austria
View Trial DetailsNCT04734015
Diabetes Mellitus, Diabetes Mellitus, Type 2
Duluth, Minnesota, United States
View Trial DetailsNCT05648383
Body Weight, Cardiovascular Diseases
Tirana, Rruga E Dibrës, Albania
View Trial DetailsNCT07587151
Diabetes Mellitus, Diabetes Mellitus, Type 2
Rockford, Illinois, United States
View Trial Details